Stack tool
Peptide Stack Builder
Select multiple research peptides and the builder will check pairwise interactions, lay out a 7-day administration schedule, and estimate the minimum weekly research mass required.
Build your research stack
Toggle peptides; the schedule and interaction check update live.
Pairwise interactions
- BPC-157 + TB-500caution
Frequently co-investigated for healing; no documented adverse pairwise interaction.
Weekly schedule
Approx. minimum weekly research mass: 6.45 mg
| Peptide | Mon | Tue | Wed | Thu | Fri | Sat | Sun |
|---|---|---|---|---|---|---|---|
| BPC-157 250 mcg · daily | |||||||
| TB-500 2000 mcg · twice weekly | |||||||
| Ipamorelin 100 mcg · daily |
How the stack logic works
The builder iterates pairwise across every selected peptide and checks the interaction dataset for documented overlaps — most commonly identical-mechanism stacks (two GLP-1 agonists, two GHRH analogs) where literature does not support concurrent investigation. Each peptide's default administration frequency (daily, twice-weekly, weekly, etc.) is then mapped to specific weekdays so that the resulting schedule respects pulsatility and half-life constraints.
Why pairwise checks matter
Two GHRH analogs (for example CJC-1295 and Tesamorelin) compete for the same receptor and provide no additive benefit — they can in fact accelerate receptor desensitisation. By contrast, the classic GHRH + GHRP pairing (CJC-1295 + Ipamorelin) is one of the best-studied research combinations because the two peptides act on distinct receptors with synergistic downstream signalling.
Supporting research
- Sigalos JT, Pastuszak AW, The Safety and Efficacy of Growth Hormone Secretagogues, Sex Med Rev, 2018.
- Khorram O et al., Effects of a GHRH analog on GH and IGF-I in older men, J Clin Endocrinol Metab, 1997.
- Frias JP et al., Tirzepatide versus Semaglutide Once Weekly, NEJM, 2021.